Mid-term Clinical Outcomes of Totally Thoracoscopic Repair for Mitral Regurgitation in Barlow’s Disease

Abstract

Abstract Objective This study aimed to confirm the safety and feasibility of totally thoracoscopic repair for mitral regurgitation (MR) in Barlow’s disease. Methods From June 2018 to December 2022, 21 consecutive Barlow's disease patients (aged 33 ± 12 years; 57.1% male) underwent totally thoracoscopic mitral valve (MV) repair with leaflets folding, multiple artificial chordae implantation and ring annuloplasty. The safety and feasibility of this technique was evaluated by its mid-term clinical outcomes. Results There was no operative death or complications. The mean cardiopulmonary bypass (CPB) time was 190 ± 41 (128–267) min, and the aortic cross-clamp time was 145 ± 32 (66–200) min. The average number of artificial chordae implantation was 2.9 ± 0.7 (1–4) pairs. During a mean follow-up time of 25.6 ± 15.2 (1–52) months, all patients showed persistent effective valve function with a mean transvalvular gradient of 1.995 ± 1.543 (1.0–6.0) mmHg and no significant MR (10 cases of mild MR) or systolic anterior motion (SAM). Conclusions Totally thoracoscopic repair was a safe, effective, and reproducible procedure with satisfied mid-term clinical outcomes for MR in Barlow’s disease. However, further randomized and long-term follow-up studies were warranted to determine its clinical effects.